Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity

Eunmi Ban; Seonghee Jeong; Mijung Park; Haejin Kwon; Jinyoung Park; Eun Joo Song; Aeri Kim

doi:10.1016/j.biopha.2019.109613

Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity

Eunmi Ban, Seonghee Jeong, Mijung Park, Haejin Kwon, Jinyoung Park, Eun Joo Song, Aeri Kim

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Abstract

Diabetic foot ulcers represent one of the major and rising health issues, as the number of diabetic patients is increasing. MicroRNAs (miRNAs) are among various bioactive molecules under investigation for diabetic wound healing. The prolonged pro-inflammatory phase in diabetic wounds partly attributes to its non-healing nature. Therefore, we hypothesized that miRNA-497, known for its regulation of inﬂammatory responses, would enhance diabetic wound healing. We screened miRNA candidates, including miRNA-497 in the wounded skin of streptozotocin-induced type 1 diabetic mice. The therapeutic potential of miRNA-497 mimic was studied by intradermal injection around the wound in diabetic mice. In addition, the effects of miRNA-497 on pro-inflammatory cytokines were analyzed in the wound lesion of diabetic mice, and in human dermal fibroblasts cells exposed to high glucose and lipopolysaccharide.We found a significant reduction of miRNA-497 expression in the dermal wounds of the diabetic mice relative to normal mice. Intradermal injection of miRNA-497 around the full-thickness dermal wounds in diabetic mice accelerated wound closure effectively compared to the control miRNA. miRNA-497 treatment in vivo and in vitro decreased representative pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Such anti-inflammatory effects of miRNA-497 shed light on its role in accelerating diabetic wound healing. In conclusion, miRNA-497, with its down-regulation activity for pro-inflammatory cytokines, is proposed as a potential therapeutic agent for diabetic wound healing.

Original language	English
Article number	109613
Journal	Biomedicine and Pharmacotherapy
Volume	121
DOIs	https://doi.org/10.1016/j.biopha.2019.109613
State	Published - Jan 2020

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) ( 2016R1D1A1B03931222 and 2017R1D1A1B03031548 ).

Publisher Copyright:
© 2019 The Authors

Keywords

Diabetic wound healing
IL-1β
IL-6
miRNA-497
TNF-α

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biopha.2019.109613

Cite this

@article{28fece92274a4d988ed0d6be92d830b2,

title = "Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity",

abstract = "Diabetic foot ulcers represent one of the major and rising health issues, as the number of diabetic patients is increasing. MicroRNAs (miRNAs) are among various bioactive molecules under investigation for diabetic wound healing. The prolonged pro-inflammatory phase in diabetic wounds partly attributes to its non-healing nature. Therefore, we hypothesized that miRNA-497, known for its regulation of inﬂammatory responses, would enhance diabetic wound healing. We screened miRNA candidates, including miRNA-497 in the wounded skin of streptozotocin-induced type 1 diabetic mice. The therapeutic potential of miRNA-497 mimic was studied by intradermal injection around the wound in diabetic mice. In addition, the effects of miRNA-497 on pro-inflammatory cytokines were analyzed in the wound lesion of diabetic mice, and in human dermal fibroblasts cells exposed to high glucose and lipopolysaccharide.We found a significant reduction of miRNA-497 expression in the dermal wounds of the diabetic mice relative to normal mice. Intradermal injection of miRNA-497 around the full-thickness dermal wounds in diabetic mice accelerated wound closure effectively compared to the control miRNA. miRNA-497 treatment in vivo and in vitro decreased representative pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Such anti-inflammatory effects of miRNA-497 shed light on its role in accelerating diabetic wound healing. In conclusion, miRNA-497, with its down-regulation activity for pro-inflammatory cytokines, is proposed as a potential therapeutic agent for diabetic wound healing.",

keywords = "Diabetic wound healing, IL-1β, IL-6, miRNA-497, TNF-α",

author = "Eunmi Ban and Seonghee Jeong and Mijung Park and Haejin Kwon and Jinyoung Park and Song, {Eun Joo} and Aeri Kim",

note = "Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) ( 2016R1D1A1B03931222 and 2017R1D1A1B03031548 ). Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2020",

month = jan,

doi = "10.1016/j.biopha.2019.109613",

language = "English",

volume = "121",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson s.r.l.",

}

TY - JOUR

T1 - Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity

AU - Ban, Eunmi

AU - Jeong, Seonghee

AU - Park, Mijung

AU - Kwon, Haejin

AU - Park, Jinyoung

AU - Song, Eun Joo

AU - Kim, Aeri

N1 - Funding Information: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) ( 2016R1D1A1B03931222 and 2017R1D1A1B03031548 ). Publisher Copyright: © 2019 The Authors

PY - 2020/1

Y1 - 2020/1

N2 - Diabetic foot ulcers represent one of the major and rising health issues, as the number of diabetic patients is increasing. MicroRNAs (miRNAs) are among various bioactive molecules under investigation for diabetic wound healing. The prolonged pro-inflammatory phase in diabetic wounds partly attributes to its non-healing nature. Therefore, we hypothesized that miRNA-497, known for its regulation of inﬂammatory responses, would enhance diabetic wound healing. We screened miRNA candidates, including miRNA-497 in the wounded skin of streptozotocin-induced type 1 diabetic mice. The therapeutic potential of miRNA-497 mimic was studied by intradermal injection around the wound in diabetic mice. In addition, the effects of miRNA-497 on pro-inflammatory cytokines were analyzed in the wound lesion of diabetic mice, and in human dermal fibroblasts cells exposed to high glucose and lipopolysaccharide.We found a significant reduction of miRNA-497 expression in the dermal wounds of the diabetic mice relative to normal mice. Intradermal injection of miRNA-497 around the full-thickness dermal wounds in diabetic mice accelerated wound closure effectively compared to the control miRNA. miRNA-497 treatment in vivo and in vitro decreased representative pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Such anti-inflammatory effects of miRNA-497 shed light on its role in accelerating diabetic wound healing. In conclusion, miRNA-497, with its down-regulation activity for pro-inflammatory cytokines, is proposed as a potential therapeutic agent for diabetic wound healing.

AB - Diabetic foot ulcers represent one of the major and rising health issues, as the number of diabetic patients is increasing. MicroRNAs (miRNAs) are among various bioactive molecules under investigation for diabetic wound healing. The prolonged pro-inflammatory phase in diabetic wounds partly attributes to its non-healing nature. Therefore, we hypothesized that miRNA-497, known for its regulation of inﬂammatory responses, would enhance diabetic wound healing. We screened miRNA candidates, including miRNA-497 in the wounded skin of streptozotocin-induced type 1 diabetic mice. The therapeutic potential of miRNA-497 mimic was studied by intradermal injection around the wound in diabetic mice. In addition, the effects of miRNA-497 on pro-inflammatory cytokines were analyzed in the wound lesion of diabetic mice, and in human dermal fibroblasts cells exposed to high glucose and lipopolysaccharide.We found a significant reduction of miRNA-497 expression in the dermal wounds of the diabetic mice relative to normal mice. Intradermal injection of miRNA-497 around the full-thickness dermal wounds in diabetic mice accelerated wound closure effectively compared to the control miRNA. miRNA-497 treatment in vivo and in vitro decreased representative pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Such anti-inflammatory effects of miRNA-497 shed light on its role in accelerating diabetic wound healing. In conclusion, miRNA-497, with its down-regulation activity for pro-inflammatory cytokines, is proposed as a potential therapeutic agent for diabetic wound healing.

KW - Diabetic wound healing

KW - IL-1β

KW - IL-6

KW - miRNA-497

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=85074568261&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2019.109613

DO - 10.1016/j.biopha.2019.109613

M3 - Article

C2 - 31707336

AN - SCOPUS:85074568261

SN - 0753-3322

VL - 121

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

M1 - 109613

ER -

Accelerated wound healing in diabetic mice by miRNA-497 and its anti-inflammatory activity

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this